- Poster presentation
- Open Access
Non-invasive focal therapy of organ confined prostate cancer with magnetic resonance guided focused ultrasound surgery
© Napoli et al; licensee BioMed Central Ltd. 2015
Published: 30 June 2015
To assess safety and effectiveness of non-invasive high intensity 3T MR guided Focused Ultrasound Surgery (MRgFUS) treatment of localized prostate cancer as salvage therapy and as an alternative to active surveillance.
14 patients with biopsy proven focal T2 prostate cancer (low-to-intermediate risk: PSA max 12 and Gleason max 3+4), confirmed on a previous multiparametric MR exam (Discovery 750, GE) including dynamic contrast enhanced (DCE) imaging (Gd-BOPTA, Bracco), underwent MRgFUS ablation (ExAblate, InSightec). 1 patient had already performed radiotherapy without clinical success, 1 patient underwent US-guided Focused Ultrasound treatment with residual tumour tissue inside the gland needing a second treatment; the last 2 enrolled patients were part of an active surveillance regimen. All patients refused radical laparoscopic prostatectomy. MRgFUS treatment was carried out on the MR identifiable lesion (max 2) using a patient specific energy (3000-8500 J) and real time MR thermometry monitor for correct treatment location. Non-perfused volume (NPV) in the post-ablative MRI was used for necrosis assessment.
Results and conclusions
Results: No significant complications were observed in all subjects during or immediately after the procedure. Post-treatment MRI demonstrated extensive coagulative necrosis at the site of sonication. At follow-up examinations 3 patients were free of residual viable tumor within the treated area; in the remaining patient, 10% of residual tumor was observed within the NPV. There was a variable amount of isolated cancer tissue (Gleason max 7, 3+4) within the non-treated parenchyma that was neither identifiable at MRI nor at biopsy.
Conclusion: Our results suggest that MR guided Focused Ultrasound Surgery is a safe and effective modality to determine >90% necrosis of identifiable prostate cancer; other prospective studies are needed to extend success rate in larger cohort.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.